ID: ALA4465625

Max Phase: Preclinical

Molecular Formula: C26H36N2O5

Molecular Weight: 456.58

Molecule Type: Unknown

Representations

Canonical SMILES:  CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccc(OCCN2CCCCC2)cc1

Standard InChI:  InChI=1S/C26H36N2O5/c1-5-31-25(29)22-18(3)27-19(4)23(26(30)32-6-2)24(22)20-10-12-21(13-11-20)33-17-16-28-14-8-7-9-15-28/h10-13,24,27H,5-9,14-17H2,1-4H3

Standard InChI Key:  ATSZNBUNXOVIFL-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 456.58

Molecular Weight (Monoisotopic): 456.2624

AlogP: 3.91

#Rotatable Bonds: 9

Polar Surface Area: 77.10

Molecular Species: BASE

HBA: 7

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 8.86

CX LogP: 3.30

CX LogD: 1.83

Aromatic Rings: 1

Heavy Atoms: 33

QED Weighted: 0.56

Np Likeness Score: -0.83

References

1. Malek R, Arribas RL, Palomino-Antolin A, Totoson P, Demougeot C, Kobrlova T, Soukup O, Iriepa I, Moraleda I, Diez-Iriepa D, Godyń J, Panek D, Malawska B, Głuch-Lutwin M, Mordyl B, Siwek A, Chabchoub F, Marco-Contelles J, Kiec-Kononowicz K, Egea J, de Los Ríos C, Ismaili L..  (2019)  New Dual Small Molecules for Alzheimer's Disease Therapy Combining Histamine H3 Receptor (H3R) Antagonism and Calcium Channels Blockade with Additional Cholinesterase Inhibition.,  62  (24): [PMID:31724859] [10.1021/acs.jmedchem.9b00937]

Source

Source(1):

• Scientific Literature